Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐ Positive and ‐Negative Myeloproliferative Neoplasms
Hematological Oncology · 2025
DOI: 10.1002/hon.70013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2025. Verfasst von Tariq I Mughal und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tufts University Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Fusion Proteins, bcr-abl, Proto-Oncogene Proteins c-bcr. Die Arbeit nennt 76 Literaturangaben. Gefördert von: Alpine Oncology Foundation.
Abstract (Originalsprache)
Despite the study of BCR::ABL1 ‐positive and ‐negative myeloproliferative neoplasms (MPNs) providing seminal insights into cancer biology, tumor evolution and precision oncology over the past half century, significant challenges remain. MPNs are clonal hematopoietic stem cell‐derived neoplasms with heterogenous clinical phenotypes and a clonal architecture which impacts the often‐complex underlying genetics and microenvironment. The major driving molecular abnormalities have been well characterized, but debate on their role as disease‐initiating molecular lesions continues. The introduction of the ABL1 tyrosine kinase inhibitors have been extremely successful in the treatment of chronic myeloid leukemia with most patients having a near‐normal life expectancy. Similar success has, however, not been achieved for BCR::ABL1 ‐negative MPNs in terms of disease course modification and most patients remain incurable. In both disease categories, genomic instability seems to increase the risk of disease progression to accelerated/blast phase, which is resistant/refractory to conventional treatment and associated with a poor prognosis. To address some of these issues, the late John Goldman and Tariq Mughal founded a scientific and clinical platform in 2006, the Post‐American Society of Hematology (ASH) MPN workshop, to appraise novel cancer biology, candidate therapeutic targets, treatments and other clinical challenges and pay tribute to all the many scientists and clinicians around the world instrumental to the progress made and continuing advances being made. This paper summarizes some of the recent data discussed at the 18 th edition of the workshop and includes reference to some data presented or published after the workshop, including the 26 th John Goldman CML conference.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tufts University Medical Center, Boston, Massachusetts, USA.
- Beckmann Research Institute of City of Hope, Duarte, California, USA.
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- MD Anderson Cancer Center, Houston, Texas, USA.
- St.Anna Children's Cancer Research Institute, Vienna, Austria.
ORCID-Profile: Tariq I Mughal
Förderung
- Alpine Oncology Foundation
Zitieren
APA
Mughal, T. I., Mascarenhas, J., Rampal, R. K., Bose, P., Lion, T., Ajufo, H., Yacoub, A., Meshinchi, S., Masarova, L., Mesa, R., Jamieson, C., Barbui, T., Saglio, G., & Van Etten, R. A. (2025). Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐ Positive and ‐Negative Myeloproliferative Neoplasms. Hematological Oncology. https://doi.org/10.1002/hon.70013
Vancouver
Mughal TI, Mascarenhas J, Rampal RK, Bose P, Lion T, Ajufo H, et al. Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐ Positive and ‐Negative Myeloproliferative Neoplasms. Hematological Oncology. 2025. doi:10.1002/hon.70013
BibTeX
@article{Mughal2025,
author = {Mughal, Tariq I and Mascarenhas, John and Rampal, Raajit K and Bose, Prithviraj and Lion, Thomas and Ajufo, Helen and Yacoub, Abdulraheem and Meshinchi, Soheil and Masarova, Lucia and Mesa, Ruben and Jamieson, Catriona and Barbui, Tiziano and Saglio, Giuseppe and Van Etten, Richard A},
title = {Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐ Positive and ‐Negative Myeloproliferative Neoplasms},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70013}
}
EUVIMED